Poxel wraps up enrollment in DESTINY-1 phase 2 trial for PXL065 in NASH
Poxel, a French biopharma company, has wrapped up patient enrollment for the phase 2 DESTINY-1 clinical trial, which is evaluating PXL065 for the treatment of NASH. An announcement in this connection was made by the company in late September. PXL065, which is a deuterium-stabilized R-stereoisomer of pioglitazone, will be evaluated for efficacy and safety in […]